Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults. Dapagliflozin is also recommended for ...

The two analyses, which represent AstraZeneca’s ongoing commitment to fully understanding the effects of dapagliflozin across subsets of patients with type 2 diabetes, will be presented at the ...